Urgent HBOT Treatment for Sudden Hearing Loss in Concord, CA

Sudden sensorineural hearing loss (SSNHL) is defined as a rapid-onset hearing loss of 30 decibels or more across at least three consecutive frequencies, occurring within 72 hours. It affects an estimated 5 to 20 people per 100,000 annually in the United States and is most common between the ages of 40 and 60, though it can occur at any age.

In most cases (approximately 85 to 90%), no specific cause is identified despite thorough evaluation — these are termed idiopathic SSNHL. Proposed mechanisms include viral infection of the cochlea or auditory nerve, vascular events causing cochlear ischemia, autoimmune injury, and intracochlear membrane rupture. The remaining cases are associated with identifiable causes such as acoustic neuroma (vestibular schwannoma), autoimmune disease, Meniere's disease, or systemic vascular conditions.

SSNHL is a medical emergency that requires immediate evaluation by an ENT (otolaryngologist) and rapid initiation of treatment. The 14-day window is critical: studies consistently show that patients who begin treatment — corticosteroids, and ideally HBOT — within two weeks of onset achieve significantly better hearing recovery than those who delay. If you experience sudden hearing loss, ringing in the ear, or a sensation of ear fullness upon waking, seek care the same day.

The inner ear (cochlea) is one of the most oxygen-sensitive structures in the human body. Its sensory hair cells have extremely high metabolic demands and almost no tolerance for hypoxia (oxygen deficiency). When blood flow or oxygenation to the cochlea is disrupted, hair cells begin to die within minutes to hours, and once lost, they do not regenerate.

HBOT corrects cochlear hypoxia by saturating the blood plasma with oxygen at pressures of 2.0 to 2.5 atmospheres, achieving tissue oxygen levels high enough to reach even the ischemic areas of the inner ear that cannot be reached by red blood cells. This directly supports survival of stressed but still-viable hair cells, reduces inflammatory damage to cochlear structures, and may restore function in cells that have been injured but not yet irreversibly lost.

The standard of care for SSNHL endorsed by the American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS) includes systemic corticosteroids as primary therapy and recommends HBOT as an adjunctive option for patients who do not respond adequately. Clinical evidence, including a systematic review published in The Laryngoscope and multiple randomized controlled trials, shows that HBOT combined with steroids produces significantly better hearing outcomes than steroids alone. Treatment is most effective when started within the first 14 days of symptom onset — contact us immediately if you are experiencing sudden hearing loss.